ID: ALA4089687

Max Phase: Preclinical

Molecular Formula: C29H23Cl2N5O2S

Molecular Weight: 576.51

Molecule Type: Small molecule

Representations

Canonical SMILES:  N/C(=N/C(=N\S(=O)(=O)c1ccc(Cl)cc1)N1CC(c2ccccc2)C(c2ccc(Cl)cc2)=N1)c1ccccc1

Standard InChI:  InChI=1S/C29H23Cl2N5O2S/c30-23-13-11-21(12-14-23)27-26(20-7-3-1-4-8-20)19-36(34-27)29(33-28(32)22-9-5-2-6-10-22)35-39(37,38)25-17-15-24(31)16-18-25/h1-18,26H,19H2,(H2,32,33,35)

Standard InChI Key:  QGGBJCCFQMWVFN-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 576.51

Molecular Weight (Monoisotopic): 575.0950

AlogP: 5.95

#Rotatable Bonds: 5

Polar Surface Area: 100.48

Molecular Species: NEUTRAL

HBA: 3

HBD: 1

#RO5 Violations: 2

HBA (Lipinski): 7

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 2

CX Acidic pKa:

CX Basic pKa: 6.59

CX LogP: 6.35

CX LogD: 6.29

Aromatic Rings: 4

Heavy Atoms: 39

QED Weighted: 0.23

Np Likeness Score: -0.84

References

1. Iyer MR, Cinar R, Katz A, Gao M, Erdelyi K, Jourdan T, Coffey NJ, Pacher P, Kunos G..  (2017)  Design, Synthesis, and Biological Evaluation of Novel, Non-Brain-Penetrant, Hybrid Cannabinoid CB1R Inverse Agonist/Inducible Nitric Oxide Synthase (iNOS) Inhibitors for the Treatment of Liver Fibrosis.,  60  (3): [PMID:28085283] [10.1021/acs.jmedchem.6b01504]

Source

Source(1):

• Scientific Literature